 |
|
Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching
Hongjo Choi, Dawoon Jeong, Young Ae Kang, Doosoo Jeon, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Jeongha Mok
Tuberc Respir Dis. 2023;86(3):234-244. Published online 2023 May 31 DOI: https://doi.org/10.4046/trd.2023.0040
|
|
Citations to this article as recorded by
 Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018–2021: A Nationwide Cross-Sectional Study
Jinsoo Min, Yousang Ko, Hyung Woo Kim, Hyeon-Kyoung Koo, Jee Youn Oh, Doosoo Jeon, Taehoon Lee, Young-Chul Kim, Sung Chul Lim, Sung Soon Lee, Jae Seuk Park, Ju Sang Kim
Tuberculosis and Respiratory Diseases.2025; 88(1): 159. CrossRef Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid
Oki Nugraha Putra, Telly Purnamasari
Tuberculosis and Respiratory Diseases.2024; 87(2): 206. CrossRef Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors’ Reply
Saerom Kim, Jeongha Mok
Tuberculosis and Respiratory Diseases.2024; 87(2): 209. CrossRef
|